Research & Analysis

Further tariffs have been taken off of the table for now, but little is known about how renewed negotiations will play out. Wendy Cutler, Vice President of the Asia Society Policy Institute weighs in on negotiations and alternative strategies for

The People’s Republic of China continues to modernize the Chinese regulatory state through its open government project, even as the Chinese Communist Party (CCP) asserts comprehensive leadership and tightens political and social controls under General Secretary Xi Jinping.

After the G20 summit in Osaka, we catch up with Jake Parker, our Vice President for China Operations in Beijing. First we cover the major developments from the G20 that are most important for foreign companies, then we get into

Why is this sector seeing openings in China while almost every other industry is facing tariffs and other barriers? This week, we speak with Angela Deng, a manager of Government Affairs at the US-China Business Council. Angela also covers the financial

This week we have our Shanghai Chief Owen Haacke on the line. First, we cover the upcoming G20 meeting between Presidents Trump and Xi, including Chinese government tone around the summit. Next, we get up to speed with USCBC’s recent

At an estimated market size of RMB 20 billion in 2018, China’s medical artificial intelligence (AI) market promises vast opportunities for US companies with innovative AI products and solutions. Yet, businesses that do not have the foresight and resources to deal with complex regulatory challenges may struggle to thrive in this competitive market. If US companies want to succeed, they must position themselves strategically and mitigate regulatory risks through clever partnerships and targeted policy advocacy.